Cellumed Co., Ltd. Overview
Cellumed is a Seoul-based medical-device and tissue-biologics company. It started as an industrial firm (Newtechman), listed on KOSDAQ in 2002, and took on its musculoskeletal and biologics identity through the 2010 merger with Korea Bone Bank. Its medical franchise rests on licensed human-tissue banking. Key products include demineralized bone matrix (Rafugen DBM, Rafugen Dental), acellular dermal matrix (the CELLUDERM family), recombinant human BMP-2 and FGF growth factors, and a titanium-alloy total-knee system. In economic terms, however, the group is now mostly a building-services contractor. Its subsidiary Hwangyeong ENG (환경이엔지), which does mechanical and fire-protection installation, produced about 93% of consolidated revenue in Q2 2026. The equity story since 2025 has been driven by solvency, not operations. A US royalty judgment, capital impairment, administrative-issue designation, repeated non-clean auditor review opinions, a change of control to an investment partnership, and a pending KRX delisting review now matter more to the valuation than product performance.
What the company does
Cellumed operates two economically distinct businesses within one listed shell.
(a) Medical / biologics (parent company). Cellumed holds a human tissue bank licence (granted 2005) and a licence to manufacture human-tissue-based medical devices (granted 2007). Under these it processes donated human tissue into:
Bone graft materials: demineralized bone matrix (DBM) in gel and powder forms for orthopaedic and spinal fusion (Rafugen DBM, Rafugen DBM Gel Pro), and dental bone graft (Rafugen Dental, also called Dental Powder).
Skin / soft-tissue grafts: acellular allogeneic dermis (CELLUDERM HD IMPLANT, CELLUDERM POWER, CELLUDERM ULTRA). Injectable forms, CELLUDERM FILL and CELLUDERM GEN, have completed development. These are used in breast reconstruction, plastic surgery, urology and "men's/women's medicine" indications.
The company also makes:
Recombinant protein biologics: rhBMP-2 (bone morphogenetic protein 2, used for bone regeneration). Cellumed describes itself as the second company in the world and the first in Asia to mass-produce rhBMP-2. It also makes FGF (fibroblast growth factor, including FGF7), which is used as a cosmetic ingredient.
Orthopaedic implants and instruments: a total-knee replacement whose femoral and tibial components are both titanium alloy (claimed to be the first such domestically produced product in Korea), spinal fixation systems, navigation systems, and 3D-printed patient-specific instruments (PSI) for knee arthroplasty.
Cosmeceuticals: the Dermycos (더미코스) line based on FGF7. It was listed at Shilla Duty Free in 2021.
Exploratory programmes: enzymes used to produce mRNA vaccines and therapeutics, through subsidiary Cellumed Biologics (founded August 2022 in Songdo, Incheon) and contract development with a German partner. In 2023 the company also announced plans for swappable-battery packs and electric two-wheelers.
(b) Construction machinery & equipment installation (subsidiaries). In 2019 Cellumed acquired InsGreen (인스그린, environmental-facilities construction) and Hwangyeong ENG (환경이엔지, general mechanical/building-services installation). Hwangyeong ENG installs HVAC, plumbing and fire-protection systems as a subcontractor to Korea's top-tier general contractors. Its projects include apartment complexes (including an LH Korea Land & Housing site in Wonju), commercial buildings (a department store renovation in Daegu) and infrastructure (Korean Air Incheon T2-related works). It reported record revenue above KRW 100 bn in FY2024 and an order backlog of about KRW 140 bn in December 2025 (Asia Economy, 4 December 2025).
Business and revenue model
| Dimension | Medical / biologics | Construction equipment installation |
|---|---|---|
| Revenue type | Product sales (tissue grafts, implants, devices, proteins, cosmetics) | Contract revenue, recognised by percentage of completion on subcontracted installation work |
| Customers | University and specialist hospitals, orthopaedic and spine surgeons, dental clinics and networks, plastic surgery and breast surgery clinics; overseas distributors for DBM | Top-tier Korean general contractors (named as a "preferred partner" by several); public housing (LH); commercial developers |
| Pricing | Largely regulated by Korea's national health-insurance reimbursement for reimbursed items; specific prices not publicly disclosed | Competitive tender / negotiated subcontract |
| Value-chain position | Tissue processor and manufacturer (sources donor tissue, partly from global suppliers per the company); also an R&D originator for recombinant proteins | Specialist subcontractor below general contractors |
| Approximate revenue share | ~7% of consolidated revenue (Q2 2026) | ~93% of consolidated revenue (Q2 2026) |
Product vs. service vs. subscription vs. licensing mix: in substance, almost all revenue is either product sales (medical) or contract/service revenue (construction). No subscription or licensing revenue is disclosed. Notably, the company has been a payer of royalties: the US Buechel-Pappas litigation relates to royalties owed for artificial-joint technology.
Company's own description vs. independent characterisation
- Company's own framing (paraphrased from the FY2025 Business Report and press releases): Cellumed calls itself a bio-medical-device manufacturer. It traces its lineage to Newtechman (1985), its KOSDAQ listing (2002), and the 2010 Korea Bone Bank merger, which took it into medical devices and biosimilars. Its press releases consistently use the label "bio medical device specialist manufacturer" (바이오 의료기기 전문 제조기업). The DART industry classification is basic pharmaceutical substances and biological products manufacturing.
Independent characterisation: By revenue, Cellumed is a building-services contractor with an attached, sub-scale tissue-biologics franchise. The medical business shrank from KRW 14.6 bn (FY2022) to KRW 14.1 bn (FY2023) and KRW 8.6 bn in 9M2024 (Dealsite, March 2025). Meanwhile construction grew to more than 87% of revenue. The medical assets (licences, FDA-listed DBM, rhBMP-2 process know-how, ADM line) carry strategic option value. This was shown by L&C Bio Group's interest in December 2025, which was later abandoned. But the medical business is not large enough to carry group overheads, litigation costs or financing needs.
Strategy
Stated strategic themes (paraphrased from FY2025-era company statements)
Following the January 2026 recapitalisation, the company stated five priorities (Asia Economy, 21 January 2026):
-
Systematic management of financial risk, with litigation debt repaid first.
-
Stabilising the internal organisation.
-
Reorganising the business portfolio around profitability.
-
Making production and supply of core products more efficient.
-
Expanding distribution and partnerships.
The new largest shareholder said it would take an active management role and pursue new bio businesses that create synergies with the existing ones. Management called 2026 the "first year" of an earnings turnaround (Asia Economy, 30 December 2025).
Initiatives announced in the last 24 months (Oct 2024 – Oct 2026)
| Date | Initiative | Description / target | Status | Source |
|---|---|---|---|---|
| Late 2024 – Feb 2025 | Production-process task force (생산공정 TFT) | Company-wide quality and process programme; DBM capacity more than 2x | Completed February 2025 | Asia Economy, 9 April 2025 |
| Apr 2025 | ISO 13485 recertification | Quality system covering bone-formation products and the knee system | Achieved | Asia Economy, 9 April 2025 |
| May–Jun 2025 | Production-led reorganisation; global raw-material sourcing | Record monthly output (May) and record monthly sales (June) for bone grafts | Achieved (monthly records) | Asia Economy, 29 May & 30 June 2025 |
| Aug 2025 | CELLUDERM HD IMPLANT upgrade; CELLUDERM FILL and GEN completed | Clinician-driven product improvement; targeting H2 2025 sales expansion | Completed | Asia Economy, 19 August 2025 |
| Aug 2025 | Litigation settlement | Settled the US award for KRW 16.56 bn, framed as removing management risk | Partly paid; renegotiated in 2026 | Asia Economy, 18 August 2025 |
| Oct–Dec 2025 | Sale of control via placement | Initially a KRW 20 bn third-party placement; first L&C Bio, then TD Landmark | Completed January 2026 (KRW 17 bn) | Dealsite |
| Dec 2025 (abandoned) | L&C Bio integration plan | Combine Cellumed's DBM, BMP and FGF technology with L&C Bio's ECM regenerative platform; existing management to acquire and spin off non-medical assets | Withdrawn 29 December 2025 | Dealsite, 23 December 2025 |
| Jan 2026 | Hwangyeong ENG 2026 operating policy | Zero serious accidents and site-centred risk management; more top-tier contractor awards | Ongoing | Asia Economy, 27 January 2026 |
| Mar 2026 | Settlement rescheduling | Retain specialist counsel; seek staggered payments; review a contribution claim against former management (co-defendant) | In negotiation; amended agreement disclosed 30 June 2026 | Hankyung, 3 March 2026; IRGO |
ESG / sustainability commitments: none disclosed.
Cost programmes with targets: none disclosed.
Medium-term financial targets / guidance
No formal quantitative guidance has been published. Qualitative statements include:
-
Expectations that 2025 would deliver record consolidated revenue. This proved correct: KRW 140.2 bn.
-
Hwangyeong ENG's backlog of about KRW 140 bn supporting continued growth (Asia Economy, 4 December 2025).
-
2026 framed as a turnaround year.
Products & Services
Medical / biologics segment
| Product / brand | Category | Description & key capabilities | Target customer | Launch / latest version | Pricing | Source |
|---|---|---|---|---|---|---|
| Rafugen DBM (라퓨젠 DBM) | Bone graft (allograft, demineralized bone matrix) | Gel-type DBM with high DBM content, intended to speed bone formation in bone defects. Company states US FDA clearance. Flagship product; process upgrade in 2025 more than doubled capacity | Orthopaedic and spine surgeons; hospitals; overseas distributors | On market; capacity upgrade completed February 2025 | — | Asia Economy, 9 April 2025; Dealsite, 10 March 2025 |
| Rafugen DBM Gel Pro | Bone graft | Gel DBM variant shown on the company website (marketed as bone for biomaterial transplantation) | Orthopaedics / spine | — | — | Dealsite, 17 April 2025 |
| Rafugen Dental (라퓨젠 덴탈) / Dental Powder | Dental bone graft | Allograft powder for dental bone augmentation; co-flagship with Rafugen DBM; record monthly output May 2025 | Dental clinics and networks | Expanded line 2023 | — | Asia Economy, 29 May 2025; Etoday, 12 June 2023 |
| Bone sponge, bone powder | Bone graft | Allograft bone substitutes for regeneration | Orthopaedics | — | — | GuruFocus description |
| CELLUDERM HD IMPLANT | Skin graft (acellular dermal matrix) | Allogeneic ADM, mainly used in breast reconstruction; cutting precision and finishing upgraded in August 2025 based on clinician feedback | Breast and plastic surgeons | Process upgrade August 2025 | — | Asia Economy (English), 19 August 2025 |
| CELLUDERM POWER | ADM | Indication-specific ADM variant | Plastic / reconstructive surgery | — | — | Asia Economy, 19 August 2025 |
| CELLUDERM ULTRA | ADM | Indication-specific ADM variant | Plastic / reconstructive surgery | — | — | Asia Economy, 19 August 2025 |
| CELLUDERM FILL | Injectable ADM | Micronised ADM in injectable form, aimed at reconstruction indications | Breast reconstruction surgeons | Development completed September 2024 | — | FY2025 Business Report; Asia Economy, 4 September 2024 |
| CELLUDERM GEN | Injectable ADM | Injectable ADM with a different ratio of purified water or biocompatible polymer carrier; intended for different, broader indications | Plastic surgery; aesthetic / other indications | Development completed by August 2025 | — | Asia Economy, 4 September 2024 & 19 August 2025 |
| Allograft tissue range (hard tissue, soft tissue, skin, spinal spacers, bio-cleanant) | Allograft | Tissue-bank-processed human tissue for transplantation | Hospitals | Ongoing | — | EMIS profile |
| rhBMP-2 reagent / BMP-2 based products (incl. BMP2 DBM gel) | Recombinant protein biologic | Recombinant human BMP-2 for bone regeneration; Cellumed claims to be the 2nd company worldwide and 1st in Asia to develop and mass-produce it | Spine / orthopaedics; research users | — | — | Dealroom; EMIS; GuruFocus |
| FGF / FGF7 recombinant proteins | Recombinant protein | Growth-factor proteins used in cosmeceutical formulations and skin regeneration R&D | Cosmetic brands; internal use | — | — | Asia Economy, 15 November 2021; Dealsite, 23 December 2025 |
| Dermycos (더미코스) | Cosmeceutical | FGF7-based skincare | Duty-free and export (China) consumers | Listed at Shilla Duty Free in 2021 | — | Asia Economy, 15 November 2021 |
| Titanium total knee replacement | Orthopaedic implant | Femoral and tibial components both in titanium alloy, described as Korea's first such domestic product; claimed to be more than 2x lighter than cobalt-chrome designs | Orthopaedic surgeons | ISO 13485 recertified April 2025 | — | Asia Economy, 9 April 2025; Dealroom |
| PSI (patient-specific instruments) | Surgical instruments | 3D-printed, patient-matched instruments for total-knee arthroplasty; AI/robotic integration targeted | Orthopaedic surgeons | Clinical expansion from 2021 | — | Asia Economy, 26 March 2021 & 15 March 2023 |
| Joint-replacement surgical robot (distribution) | Capital equipment | Sales of a knee-arthroplasty robot announced in 2021 (manufacturer not disclosed) | Hospitals | 2,021 | — | Asia Economy, 26 March 2021 |
| Spinal fixation systems | Implant | Pedicle-screw style spinal fixation | Spine surgeons | — | — | GuruFocus; EMIS |
| Navigation system | Surgical device | Orthopaedic navigation | Hospitals | — | — | GuruFocus; EMIS |
| Knee cartilage / tissue-engineering products | Tissue engineering | Demineralized bone and knee-cartilage R&D | Orthopaedics | R&D stage | — | Asia Economy, 3 September 2024 |
| Stem-cell / bio-engineering products | R&D | Listed as a portfolio category; no commercial product identified | — | — | — | EMIS |
Exploratory / non-core initiatives
| Initiative | Description | Status | Source |
|---|---|---|---|
| mRNA production enzymes | Enzymes for in-vitro transcription in mRNA vaccine and therapy manufacturing; contract development with a German party; production through Cellumed Biologics | Preparing for mass production in 2022; no commercial revenue disclosed | Asia Economy, 16 August 2022 & 3 September 2024; PatSnap |
| Swappable battery packs and e-two-wheelers | Battery solutions sourced from a Chinese battery company; local pack assembly; import and assembly of e-two-wheelers | Business objects added in 2023; still described as an ongoing pursuit in March 2024 | Asia Economy, 15 March 2023 & 7 March 2024 |
| AI-assisted surgical robotics | Integrating PSI with AI robotics through partnerships | Aspirational; no product disclosed | Asia Economy, 15 March 2023 |
Construction segment services (Hwangyeong ENG / InsGreen)
| Service line | Description | Recent references | Source |
|---|---|---|---|
| Mechanical installation (HVAC, plumbing) | Heating, cooling and air-conditioning systems for residential and commercial buildings | KRW 4.1 bn HVAC works for a large department-store renovation in Daegu (awarded December 2025; works from 2026) | Asia Economy, 4 December 2025 |
| Fire-protection systems | Sprinkler and fire-suppression installation | Named as a core capability | Asia Economy, 4 December 2025 |
| Public housing works | Installation for LH apartment projects | LH Wonju apartment project (2025) | Asia Economy, 4 December 2025 |
| Infrastructure / aviation | Works related to the Korean Air Incheon T2 IOC project | 2025 award | Asia Economy, 4 December 2025 |
| Environmental facilities (InsGreen) | Environmental plant construction | Acquired 2019 | Dealsite, 10 March 2025 |
Financial Narrative
Data limitations. Full consolidated statements for FY2021–FY2025 could not be downloaded from DART. The income-statement headline figures below come from Butler.works, which aggregates DART filings, and are cross-checked against Stockopedia (revenue) and press reports. Gross profit, EBITDA, EPS, cash flows and most balance-sheet lines are not available from the sources reviewed and are left blank. Investors should also note that the auditor issued a disclaimer of opinion on the H1 2025 and H1 2026 review reports, so the reliability of reported figures is itself in question.
Income statement (consolidated)
Sources: Butler.works (DART-derived) for revenue, operating income and net income FY2021–FY2025. FY2024 revenue, operating loss and net loss are also confirmed by Digital Today's DART summary (KRW 129.1 bn / -6.8 bn / -31.8 bn). Margins and growth rates are computed. The FY2021 growth rate uses the company-reported FY2020 revenue of KRW 91.5 bn (Asia Economy, 26 March 2021).
Revenue CAGR FY2021–FY2025: 8.8% (computed: 140.2 / 99.9 over four years).
Longer history (pre-diversification) — FY2018–FY2020
Sources: FY2019 audit report summary (filed 19 March 2020) for FY2018–FY2019; Asia Economy (26 March 2021) for FY2020. Standalone FY2020: revenue KRW 16.5 bn (+29% YoY), operating loss KRW 1.6 bn (KRW 7.9 bn better YoY).
Balance sheet
Source: Digital Today DART summary for FY2024 (assets KRW 70.2 bn, liabilities KRW 61.2 bn, equity KRW 9.1 bn; the small arithmetic gap is due to rounding).
Other balance-sheet datapoints:
Borrowings due within one year: KRW 8.9 bn. This is the latest figure cited by Dealsite on 11 March 2025, probably FY2024 year-end.
Share capital: was KRW 27.5 bn before the January 2026 placement. A 5:1 reverse split was discussed in the market as a way to cut it to KRW 5.5 bn, but management denied pursuing it (Dealsite, 21 October 2025). After the placement and CB conversions, share capital was KRW 41.6 bn (FY2025 Business Report).
March 2021 post-recapitalisation metrics: current ratio 123% and debt ratio (liabilities/equity) 63.7%, after KRW 41.4 bn of funding including a KRW 34.9 bn placement (Asia Economy, 26 March 2021).
Capital impairment: at FY2024 year-end, the capital-impairment ratio was 50% or more. A capital-impairment ratio of 50% or more (or equity below KRW 1 bn) was confirmed again at H1 2026 (KRX disclosure, 14 August 2026).
Cash flow
Line-item cash flows are not publicly disclosed in the sources reviewed. In March 2025, Dealsite reported that operating cash flow had been persistently negative and that cash outflows were becoming entrenched. Buybacks: none identified; the treasury-share ratio is 0.01% (Butler.works).
Equity financing history (third-party placements)
Sources: FY2025 Business Report (Feb 2021 KRW 13.92 bn; Feb 2024 KRW 10.00 bn; Sep 2024 KRW 2.00 bn; Apr 2025 KRW 5.00 bn). The January 2026 placement of KRW 17.0 bn falls in FY2026. The FY2025 report also notes a KRW 17.0 bn placement decision dated 10 February 2026 with TD Landmark Union No. 1 as subscriber. It is unclear whether this is a second placement or a dating of the same transaction; it is flagged as unresolved.
Ratios
FY2024 ratios are computed from the Digital Today DART summary. ROE on year-end equity is not meaningful at this level of impairment and is shown only to illustrate scale.
Aggregator ratio snapshots (dates uncertain; shown only for completeness):
-
GuruFocus: cash-to-debt 0.5; equity-to-asset 0.43; debt-to-equity 0.31; Piotroski F-score 3/9; Altman Z-score -0.17; 3-year revenue growth -4.1%. The snapshot is from a period when the share price was KRW 2,035, earlier than FY2024.
-
Stockopedia: ROE -87.5%; operating margin -19.7%; P/B 8.66; P/S 0.95.
-
StockHub (October 2026): ROE -55.7%; P/B 3.30; TTM P/E 25.2.
-
Butler.works: P/B 3.30; P/E 31.4.
The positive TTM P/E readings conflict with reported net losses. They may reflect a one-off provision reversal in a trailing period and should not be relied on.
Commentary on trends, inflections and drivers
FY2021 (peak profitability). Revenue reached KRW 99.9 bn and operating income KRW 4.7 bn, the best year in the period. Construction contributed KRW 76.1 bn, and the medical business recovered as orthopaedic surgery volumes rebounded after COVID-19. Management also credited tighter receivables management (Asia Economy, 15 November 2021).
FY2022 (top-line high, margin turn). Revenue rose 22% to KRW 122.1 bn as construction reached KRW 90.4 bn. But the group slipped to an operating loss of KRW 2.7 bn. Management blamed sharp increases in raw-material and subcontracting costs (InTheNews, 16 August 2022).
FY2023 (contraction and large net loss). Revenue fell 22% to KRW 95.6 bn as construction dropped to KRW 76.5 bn amid a Korean construction downturn. The operating loss widened to KRW 10.5 bn. The KRW 37.9 bn net loss was much larger than the operating loss, which implies large non-operating charges. Management also said capacity expansion temporarily constrained medical supply in H1 2023 (Etoday, 12 June 2023).
FY2024 (record revenue, continued losses). Revenue rebounded 35% to KRW 129.1 bn, driven by Hwangyeong ENG passing KRW 100 bn. Medical revenue fell again, which management attributed to the government–doctor dispute. The KRW 31.8 bn net loss most likely reflects recognising the US judgment liability (about KRW 24 bn) as a provision. Year-end equity fell to KRW 9.1 bn.
FY2025 (record revenue, net loss nearly eliminated). Revenue rose to a record KRW 140.2 bn, and the operating loss narrowed to KRW 5.1 bn. The net loss shrank to KRW 2.2 bn. This is consistent with the company's statement that the gap between the court award (about KRW 24 bn) and the August 2025 settlement (KRW 16.56 bn) would be written back to income (Asia Economy, 18 August 2025). The underlying operating business remained loss-making.
Structural observations:
-
Consolidated margins are those of a low-margin subcontractor. Hwangyeong ENG earned operating profit of only about KRW 1 bn-plus on revenue above KRW 100 bn in FY2024, roughly a 1% margin (Dealsite, 21 October 2025).
-
The parent's medical business was profitable at the operating level only briefly (9M2021).
-
Since 2019, the company has relied on repeated third-party placements, about KRW 70 bn in total including 2021's KRW 34.9 bn and 2026's KRW 17.0 bn, to stay solvent.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Business | Status / notes | Source |
|---|---|---|---|---|
Cellumed Co., Ltd. | Listed parent | Tissue grafts, implants, recombinant proteins, cosmeceuticals | KOSDAQ 049180; trading suspended | FY2025 Business Report |
Hwangyeong ENG (환경이엔지) | Principal subsidiary (100% per 2021 report) | Mechanical and fire-protection installation | — | Asia Economy, 26 March 2021 & 4 December 2025; Dealsite, 21 October 2025 |
InsGreen (인스그린) | Subsidiary (acquired 2019) | Environmental-facilities construction | — | Dealsite, 10 March 2025 |
Cellumed Biologics (셀루메드 바이오로직스) | Subsidiary (founded August 2022) | R&D and CDMO for mRNA-production enzymes | — | Asia Economy, 16 August 2022 |
Revenue by Segment and Revenue by Segment (%)
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Construction machinery & equipment revenue (KRW Bn) | 3.9 | 52.7 | 76.1 | 90.4 | 76.5 |
Medical devices revenue as reported (KRW Bn) | — | — | — | 14.6 | 14.1 |
Other / residual revenue, derived (KRW Bn) | — | — | — | 17.1 | 5.0 |
Total consolidated revenue (KRW Bn) | 17.9 | 91.5 | 99.9 | 122.1 | 95.6 |
Construction share of total (%) | 21.8 | 57.6 | 76.2 | 74.0 | 80.0 |
Construction revenue growth YoY (%) | — | 1,251.3 | 44.4 | 18.8 | -15.4 |
Construction by Period
| Period | Construction (KRW Bn) | Medical (KRW Bn) | Total (KRW Bn) | Construction share (%) | Source |
|---|---|---|---|---|---|
9M2024 | 80.7 | 8.6 | 92.5 | 87.3 | Dealsite, 10 March 2025 |
Q2 2026 | — | — | — | 93 (medical 7) | Butler.works (DART segment data) |
“—” = not publicly disclosed.
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 99.9 | 122.1 | 95.6 | 129.1 | 140.2 |
Revenue growth YoY (%) | 9.2 | 22.2 | -21.7 | 35.0 | 8.6 |
Operating income (KRW Bn) | 4.7 | -2.7 | -10.5 | -6.8 | -5.1 |
Net income (KRW Bn) | 8.4 | -5.4 | -37.9 | -31.8 | -2.2 |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Operating margin (%) | 4.7 | -2.2 | -11.0 | -5.3 | -3.6 |
Net margin (%) | 8.4 | -4.4 | -39.6 | -24.6 | -1.6 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet
| Metric | FY2018 | FY2019 | FY2020 |
|---|---|---|---|
Revenue (KRW Bn) | 9.9 | 17.9 | 91.5 |
Operating income (KRW Bn) | -10.9 | -8.0 | 2.4 |
Pre-tax income from continuing operations (KRW Bn) | -8.5 | -36.5 | — |
Net income (KRW Bn) | -9.8 | -37.3 | 1.8 |
Total assets (KRW Bn) | 49.6 | 65.0 | — |
Total liabilities (KRW Bn) | 26.6 | 49.3 | — |
Total equity (KRW Bn) | 23.0 | 15.7 | — |
Share capital (KRW Bn) | 10.2 | 12.2 | — |
Revenue History
| Period | Revenue (KRW Bn) | Operating income (KRW Bn) | Other | Source |
|---|---|---|---|---|
9M2021 (consolidated) | 86.8 | 3.5 | Standalone 9M revenue 10.0; standalone operating income 1.4 | Asia Economy, 15 November 2021 |
H1 2022 (consolidated) | 63.6 | -0.4 | Record H1 at the time; standalone revenue up more than KRW 10 bn YoY | InTheNews / Asia Economy, 16 August 2022 |
9M2024 (consolidated) | 92.5 | — | Construction 80.7; medical 8.6 | Dealsite, 10 March 2025 |
9M2025 (consolidated) | — | -4.5 | Loss widened YoY | Dealsite, 28 January 2026 |
Q1 2026 | — | — | EPS -21.85 (KRW) | Investing.com |
Balance Sheet (FY2024)
| Metric | FY2024 |
|---|---|
Total assets (KRW Bn) | 70.2 |
Total liabilities (KRW Bn) | 61.2 |
Total equity (KRW Bn) | 9.1 |
Financial Analysis
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividends paid (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Balance Sheet (FY2021–FY2025)
| Metric | FY2021 | FY2024 | FY2025 |
|---|---|---|---|
Third-party equity placements completed (KRW Bn) | 13.9 | 12.0 | 5.0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2024 |
|---|---|
ROE (%), on year-end equity | -349.5 |
ROA (%), on year-end assets | -45.3 |
Liabilities / equity (x) | 6.7 |
Equity / assets (%) | 13.0 |
Asset turnover (x) | 1.84 |
Share Price History
| Date | Price (KRW) | Event | Source |
|---|---|---|---|
Sep 2024 (4th) | 2,295 | +16.5% on CELLUDERM FILL completion | Asia Economy, 4 September 2024 |
25 Aug 2025 | 572 | Close, after the appeal withdrawal | Digital Today, 25 August 2025 |
16 Oct 2025 | 805 | Close on the day of the unfaithful-disclosure notice | Digital Today, 16 October 2025 |
26 Dec 2025 | 1,896 | +29.95% intraday | Twig24 / Seoul Shinmun |
30 Dec 2025 | 1,154 | -29.98% (limit-down) after L&C Bio withdrawal | Asia Economy, 30 December 2025 |
Last trade before suspension | 1,009 | Trading suspended (delisting process) | Investing.com; StockHub; Butler.works |
52-week range (pre-suspension) | 542 – 2,975 | — | Investing.com |
Metric | 1-year | 3-year | 5-year |
Share price change (%) | 11.6 | — | — |
Capital Markets
| Metric | Cellumed | Peer reference | Source |
|---|---|---|---|
Market cap (KRW Bn) | about 84.0 | L&C Bio about 1,365 | Butler.works |
P/E (TTM) | 25.2 – 31.4 (aggregators; inconsistent with reported losses; treat as unreliable) | L&C Bio: not meaningful (net loss) | StockHub; Butler.works |
P/B (x) | 3.30 | L&C Bio 4.20 | Butler.works |
EV/EBITDA (x) | Not meaningful (EBITDA not disclosed; operating loss) | — | — |
Capital Markets — Buyback authorisations
| Item | Status | Source |
|---|---|---|
Buyback authorisations | None identified; treasury shares 0.01% | Butler.works |
Moody's / S&P / Fitch ratings | Not rated | — |
Domestic credit ratings | Not identified | — |
Debt maturity profile | Not publicly disclosed. KRW 8.9 bn of borrowings was due within one year as of the latest period cited in March 2025 | Dealsite, 11 March 2025 |
Capital Markets Data
| Metric | FY2018 | FY2019 | FY2025 (post-period, Apr 2026) |
|---|---|---|---|
Share capital (KRW Bn) | 10.2 | 12.2 | 41.6 |
Analyst Conclusions
Management guidance
No quantitative guidance is published. Management described 2026 as the start of an earnings turnaround and pointed to continued growth at Hwangyeong ENG, supported by a backlog of about KRW 140 bn (Asia Economy, 30 December 2025 & 4 December 2025).
Consensus
No sell-side consensus exists.
Bull case
-
Construction keeps growing revenue. Hwangyeong ENG's backlog of about KRW 140 bn and repeat awards from top-tier contractors underpin revenue above KRW 140 bn. Even a 1–2% margin at this scale offsets parent overhead if medical losses narrow.
-
The medical assets are worth more than the listed shell implies. L&C Bio's December 2025 attempt to pay KRW 17 bn for about 34% shows strategic interest in Cellumed's DBM, BMP, FGF and ADM capabilities. At a market cap of about KRW 84 bn with about KRW 14 bn of medical revenue, a resolution could lead to a re-rating or an asset sale.
-
Litigation can be capped. Settling at KRW 16.56 bn (versus about KRW 24 bn) produced an accounting write-back. If the June 2026 amendment holds and the remaining payments are completed, the main source of the 2023–2025 losses is gone, and a recourse claim against former management could recover part of the cost.
Bear case
-
Delisting risk dominates. Shares are suspended under a KRX improvement period. The second consecutive half-year disclaimer (August 2026) cited going concern and the recoverability of loans receivable. Under the 2025 rule reform, repeated sub-standard opinions accelerate delisting.
-
Use of new money is uncertain. Reports that KRW 14.0 bn of the KRW 17.0 bn placement went to external parties, together with the auditor's concerns about loan recoverability, suggest the recapitalisation may not have strengthened the balance sheet as intended. Meanwhile settlement payments were missed (March 2026).
-
The core business is weak. Four straight years of operating losses (FY2022–FY2025), medical revenue down to about 7% of the mix, falling R&D, and growing competition in ADM and ECM limit any standalone recovery. Equity has been repeatedly impaired despite about KRW 70 bn of placements since 2021.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
| KRX decision at the end of the improvement period | likely tied to the FY2026 annual audit cycle (March–April 2027) | Determines whether the shares are delisted or trading resumes |
| FY2026 annual audit opinion | March 2027 | A clean opinion is a precondition for resuming trading |
| Outcome of the EGM (board reconstitution under TD Landmark) | Pending (notice corrected repeatedly through 27 August 2026) | Clarity on governance and control |
| Compliance with the amended settlement | Ongoing (amendment disclosed 30 June 2026) | A default could revive a liability of about KRW 24–26 bn |
| Clarification of placement-proceeds flows and loans receivable | Ongoing | Core to the auditor's concerns |
| Whether the Hwangyeong ENG buy-back by InsCobee happens | Reported condition, within one year | Could remove about 93% of revenue from the consolidated group |
| Q3 2026 quarterly report | By mid-November 2026 | Updated equity and cash position |
| Commercial uptake of CELLUDERM FILL and GEN | 2026–2027 | The medical growth thesis |
Concluding analyst verdict
Cellumed has to be analysed as a distressed listed holding company, not as an orthopaedic-biologics growth story. Its medical franchise is real. It holds tissue-bank and tissue-device licences dating from the mid-2000s, a DBM product described as FDA-cleared whose capacity doubled in 2025, recombinant rhBMP-2 and FGF know-how, a domestic titanium knee, and a refreshed acellular-dermis line that now includes injectable forms. A credible strategic buyer, L&C Bio, came close to paying KRW 17 bn for about a third of the company in December 2025. Those assets have value.
But the medical business now produces only about 7% of consolidated revenue. The group's KRW 140 bn top line is almost entirely low-margin subcontracted building-services work, and consolidated operating income has been negative every year from FY2022 to FY2025. The balance sheet has been repeatedly impaired. Equity was KRW 9.1 bn at FY2024 year-end, and capital impairment of 50% or more was re-confirmed at H1 2026.
The investment case depends on three binary outcomes. The first is the KRX delisting process now under an improvement period. The second is the auditor's ability to issue a clean FY2026 opinion after two half-year disclaimers that cited going concern and loan recoverability. The third is performance under the amended Buechel-Pappas settlement. The January 2026 recapitalisation was meant to resolve the litigation and stabilise operations, but it was followed by missed settlement instalments and unconfirmed reports that most of the proceeds left the company. That weakens confidence in governance.
On the evidence available, the downside scenarios, delisting or further dilution, are at least as likely as a clean recovery. Until the auditor's concerns and the delisting review are resolved, the reported market capitalisation of about KRW 84 bn cannot be treated as a tradable or reliable valuation. For counterparties such as suppliers, distributors and partners, the most relevant questions are continuity of supply and contract enforceability, not upside. Cellumed is best treated as a special-situation monitor, not a fundamental investment candidate.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Role | Tenure / dates | Background | Source |
|---|---|---|---|---|
Yoo In-soo (유인수) | Representative Director (CEO) | CEO until 2 April 2021; co-CEO from 9 June 2021; named as sole Representative Director in the FY2025 report (April 2026) | — | FY2025 Business Report; Asia Economy, 7 March 2024 |
Lee Seok-hwan (이석환) | Former CEO / co-CEO | — | Former CEO of SK Telecom China; former president of SK Networks ICT; led InsCobee's telecom (MVNO) business | Asia Economy, 5 April 2021 |
Yoo Jun-young (유준영) | Head of Planning Office; responsible officer for the FY2025 report | Current | — | FY2025 Business Report |
Kim Ki-ho (김기호) | Statutory auditor (감사) | Elected 31 March 2025 | — | FY2025 Business Report |
Kang Pan-heon (강판헌) | Former statutory auditor | Left 31 March 2025 | — | FY2025 Business Report |
Kang Yong-ju (강용주) | Vice President (former spokesperson for the bio business) | Quoted 2022–2023 | — | InTheNews, 2022; Etoday, 2023 |
Lee Byung-gil (이병길) | Inside director; Head of Strategic Business (battery/EV) | Nominated March 2023 | Several years as an executive at global telecom and electronics firms in China and Hong Kong | Asia Economy, 15 March 2023 |
Noh Doo-hyun (노두현) | Outside director | Nominated March 2023 | Professor of Orthopaedic Surgery, Seoul National University Hospital (BS, MS and PhD from SNU College of Medicine); founder of AI medical-robot company Connecteve | Asia Economy, 15 March 2023 |
Park Hyung-seop (박형섭) | Outside director | In office during 2024 | — | Dealsite, 17 April 2025 |
Choi Jeong-seok (최정석), Kim Jin-yeol (김진열), Yoo Chang-soo (유창수) | Former Representative Directors (dates of appointment partially visible) | — | — | FY2025 Business Report (fragment) |
Shim Young-bok (심영복) | Founder-era former CEO and former largest shareholder | Largest shareholder until April 2018 | Named as co-defendant in the Buechel-Pappas judgment | FY2025 Business Report; Dealsite, 11 March 2025 |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change | Context | Source |
|---|---|---|---|
Apr 2018 | Largest shareholder: Shim Young-bok → InsCobee | Takeover by InsCobee | FY2025 Business Report |
2 Apr 2021 | CEO: Yoo In-soo → Lee Seok-hwan | After trading resumed | Asia Economy, 5 April 2021 |
9 Jun 2021 | Co-CEOs Yoo In-soo and Lee Seok-hwan | — | FY2025 Business Report |
Mar 2023 | Lee Byung-gil (inside) and Noh Doo-hyun (outside) join | Push into battery/EV and robotics | Asia Economy, 15 March 2023 |
31 Mar 2025 | Auditor: Kang Pan-heon → Kim Ki-ho | AGM | FY2025 Business Report |
20–27 Jan 2026 | Largest shareholder: InsCobee → TD Landmark Union No. 1; business manager appointed | KRW 17 bn placement | Dealsite, 28 January 2026; IRGO |
Major Shareholders
| Holder | Shares | Stake (%) | Notes | Source |
|---|---|---|---|---|
TD Landmark Union No. 1 (티디랜드마크조합1호) | 28,192,370 | about 33.9 | Investment partnership established in 2025; described as having a bio-industry network and as related to Cellumed's business; ultimate beneficial owners not disclosed | Asia Economy, 30 December 2025; Dealsite, 16 January 2026 |
InsCobee Inc. (and related parties) | — | about 14 (press estimate) | Held 22.2% in March 2021; about 8.77 million shares locked up to March 2024; added 5,359,057 shares in 2024. Press estimated its stake at about 14% after the 2026 placement | Asia Economy, 5 April 2021 & 7 March 2024; Dealsite, 21 October 2025 |
Treasury shares | — | 0.01 | — | Butler.works |
Competitive Landscape
Key Competitors
| Competitor | Overlap with Cellumed | Scale indicator | Source |
|---|---|---|---|
L&C Bio (엘앤씨바이오, KOSDAQ 290650) | Allograft tissue, ADM (MegaDerm), ECM injectables (ELRAVIE Re2O) | FY2025 revenue KRW 85.5 bn; operating income KRW 4.4 bn; market cap about KRW 1.36 trillion | Butler.works; Alphadistill |
Hans Biomed (한스바이오메드) | Allograft skin and bone, ECM skin boosters | — | Alphadistill (as an ECM entrant) |
CGBio (시지바이오) | Bone grafts; rhBMP-2 products; ECM boosters | — | Alphadistill (as an ECM entrant) |
GC Wellbeing (GC녹십자웰빙) | ECM skin boosters | — | Alphadistill |
Osteonic (오스테오닉) | Orthopaedic / dental implants and biomaterials | — | Shinhan peer list (September 2025) |
Corentec (코렌텍) | Artificial joints (knee and hip) | — | Shinhan peer list (September 2025) |
L&K Biomed (엘앤케이바이오) | Spinal implants | — | Shinhan IR report (September 2025) |
Key Competitors — Medtronic
| Competitor | Overlap with Cellumed | Source |
|---|---|---|
Medtronic | rhBMP-2 (INFUSE), spine | — |
Johnson & Johnson (DePuy Synthes) | Joints, spine, biologics | Shinhan peer list |
Globus Medical | Spine, biologics | Shinhan peer list |
Stryker, Zimmer Biomet | Knee arthroplasty, robotics | — |
US tissue banks (MTF Biologics, LifeNet Health, AlloSource) | DBM and ADM allografts | — |
Peer Comparison FY2025
| Metric | Cellumed (FY2025) | L&C Bio (FY2025) |
|---|---|---|
Revenue (KRW Bn) | 140.2 | 85.5 |
Revenue growth YoY (%) | 8.6 | 18.6 |
Operating margin (%) | -3.6 | 5.1 |
Net income (KRW Bn) | -2.2 | -138.2 (non-cash derivative losses) |
R&D intensity (%) | not disclosed for FY2025 (2.5 in FY2023) | — |
Market cap (KRW Bn) | about 84 (suspended) | about 1,365 |



